Critical Survey: ProKidney (NASDAQ:PROK) vs. Pyxis Oncology (NASDAQ:PYXS)

Pyxis Oncology (NASDAQ:PYXS) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Volatility and Risk

Pyxis Oncology has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Pyxis Oncology and ProKidney, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1	1	8	0	2.70
ProKidney	1	0	1	1	2.67

Pyxis Oncology presently has a consensus price target of $8.75, suggesting a potential upside of 161.43%. ProKidney has a consensus price target of $12.00, suggesting a potential upside of 529.92%. Given ProKidney’s higher possible upside, analysts clearly believe ProKidney is more favorable than Pyxis Oncology.

Institutional and Insider Ownership

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Pyxis Oncology and ProKidney”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$11.04 million	25.29	-$79.62 million	($1.41)	-2.37
ProKidney	$818,000.00	704.07	-$68.99 million	($0.55)	-3.46

ProKidney has lower revenue, but higher earnings than Pyxis Oncology. ProKidney is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pyxis Oncology and ProKidney’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
ProKidney	-10,288.39%	N/A	-27.39%

Summary

ProKidney beats Pyxis Oncology on 10 of the 15 factors compared between the two stocks.

About Pyxis Oncology

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.